Alfasigma is a global private pharmaceutical company headquartered in Bologna and Milan, Italy, with a strong focus on research, development, production, and distribution of medicinal products. The company’s mission is to improve people’s health and quality of life.

Overview

Founded:
Established in 2015 through the merger of two historic Italian companies, Alfa Wassermann and Sigma-Tau.

Headquarters:
Bologna and Milan, Italy.

Global Presence:
Operates in over 100 markets worldwide, with direct subsidiaries in 24 countries, including the US, Spain, Germany, Mexico, and China.

Employees:
Employs approximately 4,000 people globally.

Therapeutic Areas and Products
Alfasigma’s product portfolio includes primary care, specialty care, rare diseases, and consumer health products. The main therapeutic areas are Gastroenterology, which is the most significant sector with products for various GI disorders including those utilizing Rifaximin-α, Vascular, addressing conditions like venous diseases and diabetic microangiopathies with molecules such as Sulodexide and Parnaparin, and Rheumatology, providing treatments for rheumatoid arthritis and axial spondyloarthritis. Alfasigma also has a presence in other areas like dermatology and cardio-metabolic health.

Operations
Alfasigma has production sites in Italy, Spain, and the United States. Research and development facilities are located in Italy.
The company also has a CDMO business unit called Morpho that offers pharmaceutical and nutraceutical solutions.